RxDoctor Payments Data

Michael Lieb, DO

Vascular Surgery · Hainesport, NJNPI 1609024447

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $54,460 of the $76,234 with a category attached, or 71.4%. Lemaitre Vascular, Inc. accounts for 67.6% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $36,050, more than ten times the $1,067 reported in 2019. Among vascular surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,234in general payments, 2019–2025

Across 289 payments — averaging $263.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lemaitre Vascular, Inc.$52K
  • Shockwave Medical, Inc$5K
  • Inari Medical, Inc.$4K
  • Boston Scientific$3K
  • Endologix LLC$2K
  • Stryker$2K
  • plus $8K from 25 others

What the payments were for

  • Consulting fees$54,46071%
  • Speaking & faculty fees$2,5503%
  • Travel & lodging$3,7455%
  • Food & beverage$15,47920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,234 in reported general payments places this provider in the 90th percentile of 182 vascular surgery providers in New Jersey.

See all vascular surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$280,086
Medicare patients
517
Services billed
1,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$14,226
EliquisApixaban20$12,667
ClopidogrelClopidogrel Bisulfate57$744
Cilostazol26$520
Atorvastatin Calcium24$353
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$157$14,22614 claims
PfizerEliquis$42$12,66720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 vascular surgery providers in New Jersey.

Other vascular surgery in Hainesport

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →